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Abstract: Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET)
can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limi-
tation may come from hematological rather than renal function, hematological peripheral blood stem
cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell
collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow
failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression
(≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle).
Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied,
and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial
failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully
performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range,
21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition
of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral
blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection
seems to be feasible in NET with bone-marrow involvement and might be worth considering as a
backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.
Keywords: peptide receptor radionuclide therapy; PRRT; neuroendocrine tumor; NET; peripheral
blood stem cell collection; PBSC; hematotoxicity
1. Introduction
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is a longstand-
ing systemic treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-
NET) [1–3]. Over recent years, several studies have reported remarkable results of in-
dividualized PRRT schemes for selected patients in different settings [4–14]. However,
the only conducted randomized phase III trial (NETTER-1) demonstrating the efficacy of
PRRT was limited to patients with midgut NET receiving a “standard treatment scheme”
consisting of four cycles with a predefined administered activity of 7.4 GBq per cycle every
8 weeks [15]. Therefore, identifying other eligible patients for PRRT, appropriate treatment
individualizations, and baseline characteristics influencing the outcome mainly relies on
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data from retrospective studies [16–20]. To date, ki67-index <20% and limited liver tumor
burden are considered as the main favorable prognostic factors for NET patients undergo-
ing PRRT, irrespective of the primary tumor [8,21,22]. Patients with advanced metastatic
bone involvement, on the other hand, are at higher risk of bone-marrow impairment and
are treated cautiously to avoid severe irreversible myelotoxicity [23–25]. In view of the
low overall toxicity of PRRT, especially the low nephrotoxic potential of 177Lu-DOTATATE,
myelosuppression may also be the cumulative dose-limiting toxicity in responsive patients,
restricting the application of repeat PRRT cycles [2,26–28].
Autologous peripheral blood stem-cell transplantation is widely used after myeloab-
lative treatments in a variety of hematological malignancies and solid tumors. Peripheral
blood is the usual source of stem cells, providing a safe and easily accessible route for
isolating autologous stem cells [29,30]. Different strategies have been applied to optimize
the mobilization and collection of peripheral blood stem cells (PBSC), especially in patients
with risk factors for poor mobilization such as bone-marrow involvement [31,32]. To the
best of our knowledge, this concept has not yet been considered for PRRT and it remains
unclear whether PBSC can be collected in bone metastatic NET disease. If proven successful
and safe, autologous transplantation of PBSC may encourage the use of higher activities
and more cycles, especially in patients with advanced metastatic disease and very few
therapeutic options, increasing the clinical benefit and expanding the indications for PRRT.
In this paper we introduce and discuss the feasibility of PBSC collection in NET patients
with metastatic bone-marrow spread.
2. Methods
Five patients with bone-marrow infiltration of NET and cytopenia on complete blood
counts (≥grade 2 according to CTCAE v5.0) received PBSC apheresis 8 ± 4 weeks before the
onset (n = 2) or in the interval of two 177Lu-DOTATATE administrations (n = 3). PRRT was
performed with 7.6 ± 0.8 GBq 177Lu-DOTATATE per cycle at standard intervals of 3 months
using a previously described protocol [22]. Prior to PBSC, standard stem-cell mobilizing
agent granulocyte-colony stimulating factor (G-CSF) was applied subcutaneously at 10
µg/kg/day for at least 4 days to achieve CD34+ cell counts ≥ 10/µL as the prerequisite for
the apheresis. Successful PBSC was defined as >2 × 106/kg CD34+ cells [31]. If adequate
numbers of stem cells could not be mobilized, the selective CXCR4 antagonist Plerixafor
was added to G-CSF to enhance the outcome (2,40 mg/kg s.c.,10 h before apheresis) [32,33].
Table 1 provides tumor- and treatment-related characteristics of the patient cohort.
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liver, bone G-CSF,Plerixafor Successful 37.3 GBq (5) 7.5 GBq (1) PR
CUP, cancer of unknown origin; SSA, somatostatin receptor analogues; CTx, chemotherapy; STZ, streptozotocin; Dox, doxorubicin;
Cis, cisplatin; 5FU, 5-fluorouracil; PRRT, peptide receptor radionuclide therapy.
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3. Results
All patients had relevant cytopenia (≥grade II) of at least one blood cell line at the
time of apheresis. Three patients had anemia (two grade II, and one grade III), two patients
had thrombocytopenia (one grade III, and one grade IV), and three patients had leukopenia
(one grade II, and two grade III). The median cumulative activity of 177Lu-DOTATATE
was 44.8 GBq (range, 21.3–62.4; mean, 42.1). PBSC was successfully performed in all five
patients. Two of three patients with progressive disease under chemotherapy showed
relevant cytopenia at baseline and received PBSC prior to initiation of PRRT, adequate
mobilization was achieved in both with G-CSF only. In contrast, two of three patients
previously treated with PRRT required additional Plerixafor to achieve >2 × 106/kg CD34+
cells. During the mean follow-up of 28 months, one patient required autologous stem-cell
support because of severe cytopenia (thrombocytopenia, grade IV; neutropenia, grade III)
70 days after the completion of PRRT. Blood counts recovered to near normal (grade I
thrombocytopenia, normal neutrophil and leukocyte counts) 6 weeks after the procedure.
In the other four patients, the harvested PBSC remained stored as back-up material in
case of future bone-marrow failure. Figure 1 illustrates 68Ga-DOTATOC PET images of a
patient with renal NET treated with 29 GBq 177Lu-DOTATATE prior to PBSC harvesting.
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Figure 1. Maximum-intensity-projection 68Ga-DOTATOC PET images of a patient with renal NET before (A) and after (B)
four cycles of 177Lu-DOTATATE (29 GBq) showing initial response. Repeat PRRT was performed 14 months later because
of progressive disease (C) after successful PBSC harvesting and almost achieved disease stabilization (D) after 2 cycles
(15.4 GBq) of re-PRRT and partial response (E) after additional 3 cycles (18 GBq).
4. Discussion
This preliminary report introduces the concept of PBSC in high-risk patients with
advanced bone-marrow involvement of NET undergoing PRRT, describing a successful
procedure in five patients with bone-marrow impairment at the time of apheresis.
Few therapeutic options exist for patients with advanced stage metastatic NET. PRRT
with 177Lu-DOTATATE is a potent systemic treatment modality for metastatic NET with a
low overall toxicity profile. However, the risk of therapy-induced bone-marrow failure re-
stricts the application of sufficiently high activities in patients with extensive bone-marrow
infiltration. Similarly, patients with low or decreasing hematological parameters are gener-
ally treated with reduced activities, leading to suboptimal treatment outcomes in patients
with high tumor load or a clinical need for tumor remission. Patients with significant
cytopenia of ≥grade III are often discarded from PRRT [23,25,34]. For a substantial portion
of patients with metastatic NET undergoing PRRT, it may persist as a long-term pallia-
tive treatment as it can reinduce tumor response once re-progression occurred [16,35–37].
However, cumulative absorbed dose to bone marrow would eventually limit the appli-
cation [38,39]. Moreover, long survival of NET patients allows for the clinical occurrence
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of myelodysplastic syndrome, a potential late sequel of alkylating chemotherapy and
systemic radionuclide therapies [40].
If proved feasible in clinical practice, autologous transplantation of PBSC may con-
tribute to overcome the dose-limiting hematotoxicity, allowing dose escalations or repeat
PRRT cycles in selected patients. This approach has been successfully used in patients with
malignant pheochromocytomas and paragangliomas treated with 131I-Metaiodobenzylguan
idine (131I-MIBG). In a phase II study by Fitzgerald et al., PBSC collection at baseline en-
abled an individualized high-dose treatment with a mean of 833 mCi (557–1185 mCi) in
30 patients. In 4/30 patients, bone-marrow support was needed after the treatment and
effectively prevented irreversible myelosuppression [41]. Similarly, in our series, blood
counts of the patient with severe cytopenia recovered after autologous peripheral blood
stem-cell transplantation.
Hematopoietic growth factors like G-CSF are used for releasing stem cells from the
bone marrow into the peripheral blood. The selective CXCR4 antagonist AMD3100 (Pler-
ixafor) [42,43], has been proven to enhance PBSC collection in cancer patients and is
established for this purpose, especially in case of mobilization issues [33]. Plerixafor was
used in two of our patients to achieve sufficient cell mobilization. Therefore, the most
appropriate time point for prophylactic PBSC remains to be determined. Although PBSC
would possibly be easier prior to initiation of PRRT [32], collection at later time points (e.g.,
after two cycles) may facilitate the assessment of risk for developing bone-marrow failure
under therapy. In our small cohort, successful PBSC was possible in all patients even after
high cumulative activities of 177Lu-DOTATATE.
5. Conclusions
Prophylactic PBSC seems technically feasible in patients with advanced bone metastatic
NET, even after PRRT with high cumulative activity. The procedure might be worth con-
sidering especially in high-risk candidates in an attempt to overcome the dose-limiting
hematological toxicity of PRRT.
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